Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China To Review Use Of Chinese Herbal Injections

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health has held an emergency videoconference to announce the adverse reactions of four newborn babies who were injected with Yinzhihuang herbal medicine. The drug produced by Shanxi Taihang Pharmaceutical has caused one death and the authorities are calling for an immediate recall. From Yuxingcao and Ciwujia to Yinzihuang, controversy and drug safety incidents have been plaguing Chinese herbal injections since they emerged as a new profit stream in the pharmaceutical industry. Experts note that to ensure such products' safety and quality, China's State FDA issued basic technical requirements for traditional Chinese medicine and natural medicine injections last December but the regulations have not been fully implemented. To prevent further incidents, the government should expand more clinical trial coverage and establish an effective adverse drug reaction reporting system. (Click here for more - Chinese Language)

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts